About
Veloxis is a speciality pharmaceutical company focused on the development and commercialization of Envarsus® (LCP-Tacro) for the prevention of organ rejection in kidney transplant patients. Envarsus® is a once-daily dosage version of tacrolimus, the market-leading primary immunosuppressant in the transplant market, and has successfully demonstrated non-inferiority compared to Prograf® in its two Phase III clinical trials, Study 3001 (stable kidney transplant patients) and Study 3002 (de novo kidney transplant patients). In April 2013, the company submitted a marketing authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval to market Envarsus® for the prevention of organ rejection in kidney transplant patients in the European Union. In December 2013, the company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of Envarsus® for the prevention of organ rejection in kidney tra
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
- • 3 investors are based in Hørsholm, Hovedstaden, Denmark.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- healthtech biotech
- Location
- Hørsholm, Denmark
Contact Information
Find more investors like Veloxis
Search Investors